Media Coverage
July 2025 – Forbes
InnovationRx: The Secretive Company Hawking Bad Health Advice On Facebook Read More »
July 2025 – PharmaVoice
The MEK effect on cancer — a slow and steady approach to drug resistance Read More »
June 2025 – Targeted Oncology
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer Read More »
June 2025 – OncLive
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer Read More »
June 2025 – Fierce Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans Read More »
June 2025 – Cancer Network
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC Read More »
June 2025 – FirstWord Pharma
Immuneering touts strong survival in pancreatic cancer trial Read More »
June 2025 – Endpoints News
Immuneering says MEK pill beats standard of care in first-line pancreatic cancer Read More »
Page 1 of 1
